Lincocin (Lincomycin)

Lincomycin binds to the 50S subunit of bacterial ribosomes, blocking the translocation step of protein synthesis. This inhibition prevents the formation of peptide bonds, halting bacterial growth and producing a bacteriostatic effect against susceptible organisms.

The dosage of Lincocin is individualized by the prescribing clinician according to the type and severity of infection, patient weight, renal and hepatic function, and susceptibility data. Dosage regimens are provided in the product label and must be followed as directed.

Safety of lincomycin during pregnancy or lactation has not been fully established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified health professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to lincomycin is clindamycin, another lincosamide. Both share a similar mechanism of action, but clindamycin generally has a broader spectrum against anaerobes and better oral bioavailability. Lincomycin may be preferred in regions where clindamycin resistance is high or when specific susceptibility data support its use.

Lincocin should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in damp or excessively hot environments, and discard any product that appears discolored or compromised.

Lincocin is supplied as an oral dosage form and is taken by mouth with or without food, as directed by the prescribing clinician. The tablets or capsules should be swallowed whole with a glass of water. Patients should follow the prescribed schedule and complete the full course, even if symptoms improve earlier.

Serious adverse reactions associated with lincomycin include Clostridioides difficile‑associated colitis, severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, liver toxicity, neutropenia and thrombocytopenia. Patients should seek immediate medical attention if they develop persistent diarrhea, rash, jaundice, fever, or signs of bleeding while on therapy.

Lincocin is contraindicated in individuals with a known hypersensitivity to lincomycin, other lincosamides, or any component of the formulation. It should also be avoided in patients with a history of severe colitis caused by C. difficile. Caution is advised in patients with significant hepatic or renal impairment, and the drug should be used only under medical supervision in these populations.